Psychopharmacology

, 207:119 | Cite as

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors

  • Shona L. Kirk
  • John Glazebrook
  • Ben Grayson
  • Joanna C. Neill
  • Gavin P. Reynolds
Original Investigation

Abstract

Introduction

Substantial increases in body weight can be induced by several antipsychotic drugs, most notably olanzapine and clozapine. Antagonism at certain receptors, particularly 5-HT2C and histamine H1 receptors, is implicated in this effect.

Materials and methods

We have investigated the contribution of effects at these receptors to olanzapine-induced weight gain occurring over 5 days following daily intraperitoneal drug injections in groups of eight female rats.

Results

Olanzapine (2 mg/kg) and the 5-HT2C antagonist SB 243213 (1 mg/kg), but not the histamine H1 antagonist mepyramine (1 mg/kg), produced significant increases in percentage body weight above vehicle; olanzapine showed a significantly greater effect than SB 243213. Haloperidol (0.1 mg/kg) alone or with mepyramine had no significant effects on weight gain, while with SB 243213 and with both SB 243213 and mepyramine, it showed olanzapine-like increases in weight.

Conclusion

These results suggest that 5-HT2C receptor antagonism or inverse agonism, in the presence of D2 receptor antagonism, may contribute to olanzapine-induced weight gain.

Keywords

Antipsychotic drug Olanzapine Weight gain Rat 5-HT2C receptor Histamine H1 receptor 

References

  1. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36–51CrossRefGoogle Scholar
  2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMedGoogle Scholar
  3. Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405CrossRefPubMedGoogle Scholar
  4. Berg KA, Navailles S, Sanchez TA, Silva YM, Wood MD, Spampinato U, Clarke WP (2006) Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses. J Pharmacol Exp Ther 319:260–268CrossRefPubMedGoogle Scholar
  5. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36:621–629CrossRefPubMedGoogle Scholar
  6. Clifton PG, Lee MD, Dourish CT (2000) Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berl) 152:256–267CrossRefGoogle Scholar
  7. Cooper SJ, Al-Naser HA (2006) Dopaminergic control of food choice: contrasting effects of SKF 38393 and quinpirole on high-palatability food preference in the rat. Neuropharmacology 50:953–963CrossRefPubMedGoogle Scholar
  8. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80–89CrossRefGoogle Scholar
  9. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford G, Goudie AJ (2007) Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21:405–413CrossRefPubMedGoogle Scholar
  10. Davoodi N, Kalinichev M, Clifton PG (2008) Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav Pharmacol 19:121–128CrossRefPubMedGoogle Scholar
  11. Fell MJ, Marshall KM, Williams J, Neill JC (2004a) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149–155CrossRefPubMedGoogle Scholar
  12. Fell MJ, Neill JC, Marshall KM (2004b) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur Neuropsychopharmacol 14:385–392CrossRefPubMedGoogle Scholar
  13. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC (2007) The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 194:221–231CrossRefGoogle Scholar
  14. Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K, Wada H (1989) Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol 256:R605–611PubMedGoogle Scholar
  15. Gilbert DB, Cooper SJ (1985) Analysis of dopamine D1 and D2 receptor involvement in d- and l-amphetamine-induced anorexia in rats. Brain Res Bull 15:385–389CrossRefPubMedGoogle Scholar
  16. Han M, Deng C, Burne TH, Newell KA, Huang XF (2008) Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 33:569–580CrossRefPubMedGoogle Scholar
  17. Hartfield AW, Moore NA, Clifton PG (2003) Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76:251–258CrossRefPubMedGoogle Scholar
  18. Hayashi A, Suzuki M, Sasamata M, Miyata K (2005) Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats. Psychopharmacology (Berl) 178:241–249CrossRefGoogle Scholar
  19. Hernandez L, Hoebel BG (1988) Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. Physiol Behav 44:599–606CrossRefPubMedGoogle Scholar
  20. Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226–232PubMedGoogle Scholar
  21. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ (1997) Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121:1613–1618CrossRefPubMedGoogle Scholar
  22. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 182:220–231CrossRefGoogle Scholar
  23. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620CrossRefPubMedGoogle Scholar
  24. Kirk SL, Neill JC, Jones DN, Reynolds GP (2004) Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 505:253–254CrossRefPubMedGoogle Scholar
  25. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519–526CrossRefPubMedGoogle Scholar
  26. Lecklin A, Tuomisto L (1998) The blockade of H1 receptors attenuates the suppression of feeding and diuresis induced by inhibition of histamine catabolism. Pharmacol Biochem Behav 59:753–758CrossRefPubMedGoogle Scholar
  27. Martel P, Fantino M (1996) Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav 53:221–226CrossRefPubMedGoogle Scholar
  28. Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20:368–378CrossRefPubMedGoogle Scholar
  29. Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46:254–262CrossRefPubMedGoogle Scholar
  30. Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83–89PubMedGoogle Scholar
  31. Reynolds GP (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18:340–345CrossRefPubMedGoogle Scholar
  32. Sakata T, Ookuma K, Fukagawa K, Fujimoto K, Yoshimatsu H, Shiraishi T, Wada H (1988) Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 441:403–407CrossRefPubMedGoogle Scholar
  33. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57–73CrossRefGoogle Scholar
  34. Snigdha S, Thumbi C, Reynolds GP, Neill JC (2008) Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 22:567–71CrossRefPubMedGoogle Scholar
  35. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357:354–357CrossRefPubMedGoogle Scholar
  36. Wetterling T (2001) Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59–73CrossRefPubMedGoogle Scholar
  37. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358–363PubMedGoogle Scholar
  38. Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Shona L. Kirk
    • 1
  • John Glazebrook
    • 2
  • Ben Grayson
    • 2
  • Joanna C. Neill
    • 2
  • Gavin P. Reynolds
    • 1
  1. 1.Department of PsychiatryQueen’s University BelfastBelfastUK
  2. 2.Bradford School of PharmacyUniversity of BradfordBradfordUK

Personalised recommendations